Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply

Jonathan I. Silverberg, Emma Guttman-Yassky, Renata Gontijo Lima

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)2299-2300
Number of pages2
JournalNew England Journal of Medicine
Volume388
Issue number24
DOIs
StatePublished - 15 Jun 2023

Cite this